Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate ...

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.